PUBLISHER: TechNavio | PRODUCT CODE: 2109503
PUBLISHER: TechNavio | PRODUCT CODE: 2109503
Global Cancer Biologics Market 2026-2030
The global cancer biologics market is forecasted to grow by USD 68000.8 mn during 2025-2030, accelerating at a CAGR of 8.2% during the forecast period. The report on the global cancer biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating prevalence of oncology indications and aging demographics, technological advancements in recombinant dna and antibody engineering, favorable regulatory frameworks and expedited approval pathways.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 7.8% |
| CAGR | 8.2% |
| Incremental Value | $68000.8 mn |
Technavio's global cancer biologics market is segmented as below:
By Product
- Monoclonal antibodies
- Cell and gene therapy
- Vaccines
- Others
By Route Of Administration
- Injectable
- Oral
By Type
- Breast cancer
- Lung cancer
- Prostate cancer
- Colorectal cancer
- Others
By End-User
- Hospitals
- Specialized cancer centers
- Academic and research institutes
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the proliferation of personalized medicine and precision oncology as one of the prime reasons driving the global cancer biologics market growth during the next few years. Also, expansion of biosimilar adoption and market penetration and integration of ai and ml in drug discovery will lead to sizable demand in the market.
The report on the global cancer biologics market covers the following areas:
- Global cancer biologics market sizing
- Global cancer biologics market forecast
- Global cancer biologics market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global cancer biologics market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Biocon Ltd., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Inc., CSL Ltd., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Jazz Pharmaceuticals Plc, Johnson and Johnson, Kite Pharma Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Organon and Co., Pfizer Inc., Sanofi SA. Also, the global cancer biologics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Product
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Cancer Biologics Market 2020 - 2024
- Historic Market Size - Data Table on Global Cancer Biologics Market 2020 - 2024 ($ million)
- 5.2 Product segment analysis 2020 - 2024
- Historic Market Size - Product Segment 2020 - 2024 ($ million)
- 5.3 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.4 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.5 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.6 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.7 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global cancer biologics market
- 6.2 Impact of geopolitical conflicts on global cancer biologics market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Product
- 8.1 Market segments
- 8.2 Comparison by Product
- 8.3 Monoclonal antibodies - Market size and forecast 2025-2030
- 8.4 Cell and gene therapy - Market size and forecast 2025-2030
- 8.5 Vaccines - Market size and forecast 2025-2030
- 8.6 Others - Market size and forecast 2025-2030
- 8.7 Market opportunity by Product
- Market opportunity by Product ($ million)
9 Market Segmentation by Route of Administration
- 9.1 Market segments
- 9.2 Comparison by Route of Administration
- 9.3 Injectable - Market size and forecast 2025-2030
- 9.4 Oral - Market size and forecast 2025-2030
- 9.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
10 Market Segmentation by Type
- 10.1 Market segments
- 10.2 Comparison by Type
- 10.3 Breast cancer - Market size and forecast 2025-2030
- 10.4 Lung cancer - Market size and forecast 2025-2030
- 10.5 Prostate cancer - Market size and forecast 2025-2030
- 10.6 Colorectal cancer - Market size and forecast 2025-2030
- 10.7 Others - Market size and forecast 2025-2030
- 10.8 Market opportunity by Type
- Market opportunity by Type ($ million)
11 Market Segmentation by End-user
- 11.1 Market segments
- 11.2 Comparison by End-user
- 11.3 Hospitals - Market size and forecast 2025-2030
- 11.4 Specialized cancer centers - Market size and forecast 2025-2030
- 11.5 Academic and research institutes - Market size and forecast 2025-2030
- 11.6 Market opportunity by End-user
- Market opportunity by End-user ($ million)
12 Customer Landscape
- 12.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape
- 13.1 Geographic segmentation
- 13.2 Geographic comparison
- 13.3 North America - Market size and forecast 2025-2030
- 13.3.1 US - Market size and forecast 2025-2030
- 13.3.2 Canada - Market size and forecast 2025-2030
- 13.3.3 Mexico - Market size and forecast 2025-2030
- 13.4 Europe - Market size and forecast 2025-2030
- 13.4.1 Germany - Market size and forecast 2025-2030
- 13.4.2 UK - Market size and forecast 2025-2030
- 13.4.3 France - Market size and forecast 2025-2030
- 13.4.4 Italy - Market size and forecast 2025-2030
- 13.4.5 Spain - Market size and forecast 2025-2030
- 13.4.6 The Netherlands - Market size and forecast 2025-2030
- 13.5 Asia - Market size and forecast 2025-2030
- 13.5.1 China - Market size and forecast 2025-2030
- 13.5.2 Japan - Market size and forecast 2025-2030
- 13.5.3 India - Market size and forecast 2025-2030
- 13.5.4 South Korea - Market size and forecast 2025-2030
- 13.5.5 Taiwan - Market size and forecast 2025-2030
- 13.5.6 Thailand - Market size and forecast 2025-2030
- 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 13.6.1 Brazil - Market size and forecast 2025-2030
- 13.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 13.6.3 UAE - Market size and forecast 2025-2030
- 13.6.4 South Africa - Market size and forecast 2025-2030
- 13.6.5 Argentina - Market size and forecast 2025-2030
- 13.6.6 Turkey - Market size and forecast 2025-2030
- 13.6.7 Israel - Market size and forecast 2025-2030
- 13.6.8 Chile - Market size and forecast 2025-2030
- 13.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
14 Drivers, Challenges, and Opportunity
- 14.1 Market drivers
- Escalating prevalence of oncology indications and aging demographics
- Technological advancements in recombinant DNA and antibody engineering
- Favorable regulatory frameworks and expedited approval pathways
- 14.2 Market challenges
- High manufacturing costs and complex production processes
- Stringent regulatory hurdles and extended approval timelines
- Reimbursement complexities and substantial treatment costs
- 14.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 14.4 Market opportunities
- Proliferation of personalized medicine and precision oncology
- Expansion of biosimilar adoption and market penetration
- Integration of AI and ML in drug discovery
15 Competitive Landscape
- 15.1 Overview
- 15.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 15.3 Landscape disruption
- Overview on factors of disruption
- 15.4 Industry risks
- Impact of key risks on business
16 Competitive Analysis
- 16.1 Companies profiled
- Companies covered
- 16.2 Company ranking index
- Company ranking index
- 16.3 Market positioning of companies
- Matrix on companies position and classification
- 16.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 16.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 16.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 16.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 16.8 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 16.9 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 16.10 CSL Ltd.
- CSL Ltd. - Overview
- CSL Ltd. - Business segments
- CSL Ltd. - Key offerings
- CSL Ltd. - Segment focus
- SWOT
- 16.11 Dr. Reddys Laboratories Ltd.
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key news
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Segment focus
- SWOT
- 16.12 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- 16.13 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 16.14 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 16.15 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 16.16 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 16.17 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 16.18 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
17 Appendix
- 17.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 17.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 17.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 17.4 Research methodology
- Research methodology
- 17.5 Data procurement
- Information sources
- 17.6 Data validation
- Data validation
- 17.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 17.8 Data synthesis
- Data synthesis
- 17.9 360 degree market analysis
- 360 degree market analysis
- 17.10 List of abbreviations
- List of abbreviations
